Clinical Trial Update: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy, safety and tolerability of remibrutinib in adults with peanut allergy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peanut Allergy

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Allergy, Peanut | Phase 2 | Status: COMPLETED